Genzyme Europe

Company snapshot

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the

• 20 active pipeline program(s) linked via ClinicalTrials.gov.
• 24 US patent(s) indexed to this assignee profile.
• 20 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Genzyme Europe. Not investment advice.

• Peer + 0 momentum

  Biocryst

  TA overlap score 27.4

• Peer + 0 momentum

  Akari Therapeutics

  TA overlap score 21.8

• Peer + 0 momentum

  Eledon Pharmaceuticals

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for Genzyme Europe.

1. Jun 8, 2026 Clinical update

   Virtual Reality (VR) Contrast Function Test — Unknown

2. Jun 8, 2026 Clinical update

   Pegcetacoplan — Phase 2

3. Jun 8, 2026 Clinical update

   PEGCETACOPLAN (APL-2) — Phase 3

4. Jun 8, 2026 Clinical update

   APL-3007, pegcetacoplan (APL-2) — Phase 2

5. Jun 8, 2026 Clinical update

   APL-2, Pegcetacoplan — Phase 3

View all clinical trial activity →

• What is Genzyme Europe?

  Genzyme Europe is a pharma organization headquartered in WALTHAM, MA, NL. It trades on NYSE under ticker APLS. Primary therapeutic focus areas include Geographic Atrophy, Geographic Atrophy Secondary to Age-related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria, FSGS,

• Is Genzyme Europe publicly traded?

  Yes. Genzyme Europe is listed with ticker APLS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Genzyme Europe develop or market?

  We link 5 drug profile(s) where Genzyme Europe is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/apellis-pharmaceuticals#company-drugs.

• What are the latest developments for Genzyme Europe?

  In the last 12 months our linked public records show 20 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Genzyme Europe focus on?

  Genzyme Europe focuses on Geographic Atrophy, Geographic Atrophy Secondary to Age-related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria based on our analysis of their pipeline programs and drug development activities.